Alzheimer’s disease is undoubtedly the major health challenge of our Century with significant social and economic consequences. This Frontiers eBook offers a contribution of 39 innovative papers on the multidimensional and crucial problem of Alzheimer’s disease management and treatment. Several perspectives, research updates, and trials describing methods on potential diagnosis and treatment are presented including biological mechanisms, biomarkers and risk factors for an early and efficient prognosis, diagnosis and prevention. Additionally, while the rapidly increasing Alzheimer’s disease population demands holistic solutions and clinical studies with new therapeutic target approaches, several of the contributive papers present promising drugs targeting Alzheimer’s disease treatment. We give our deepest acknowledgment to all the authors for their important and innovative contributions, to the reviewers for their valuable recommendations on improving the submitting studies and all the Frontiers Editorial team for continuous support.

Given the success of Volume I of this Research Topic, we are pleased to announce the launch of Volume II: “The Alzheimer's Disease Challenge”. The repeated failure of clinical trials on the amyloid-based medications and the pessimistic calculations of Alzheimer's disease cost burden for the next few decades present a severe challenge to humankind with severe social implications. In recent years, several alternative diagnostic and treatment procedures have been presented to treat and manage Alzheimer’s disease as it has been nearly impossible to suggest a holistic solution. Several revelations in human biology have highlighted the multiparametric character of the disease. Besides the amyloid aggregation and neurofibrillary tangles that result in Aβ toxicity and tau phosphorylation, processes such as Gene Mutations, Proteins Misfolding, Brain Biochemical and Histopathological Changes, Behavioral Changes, Nutrition and Metabolism Alterations, and Autonomic Dysfunctions due to Central Nervous System dysregulations are common signs and probably early diagnostic biomarkers in most of the Alzheimer's classification categories.

Society today, writes Stephen Post, is "hypercognitive": it places inordinate emphasis on people's powers of rational thinking and memory. Thus, Alzheimer disease and other dementias, which over an extended period incrementally rob patients of exactly those functions, raise many dilemmas. How are we to view—and value—persons deprived of what some consider the most important human capacities? In the second edition of The Moral Challenge of Alzheimer Disease, Post updates his highly praised account of the major ethical issues relating to dementia care. With chapters organized to follow the progression from mild to severe and then terminal stages of dementia, Post discusses topics including the experience of dementia, family caregiving, genetic testing for Alzheimer disease, quality of life, and assisted suicide and euthanasia. New to this edition are sections dealing with end-of-life issues (especially artificial nutrition and hydration), the emerging cognitive-enhancing drugs, distributive justice, spirituality, and hospice, as well as a critique of rationalistic definitions of personhood. The last chapter is a new summary of practical solutions useful to family members and professionals.

Alzheimer's infection (AD) is the most well-known type of dementia among more seasoned individuals. Dementia is a mental problem that truly influences an individual's capacity to complete day-to-day exercises. Promotion starts gradually. It initially includes the pieces of the mind that control thought, memory, and language. Individuals with AD might experience difficulty recalling things that happened as of late or the names of individuals they know. A connected issue, gentle mental impedance (MCI), causes more memory issues than typical for individuals of a similar age. Many, but not all, individuals with MCI will foster AD. If your cherished one has been determined to have Alzheimer's, be arranged for anything — it tends to be a stunning sickness. This book gives a method for seeing this excursion a piece in an unexpected way, not as a rundown of difficulties, but rather as a method for growing your heart and changing how you treat others. It gives instances of how to embrace the best outlook for managing this drawn-out illness. The creator strolls through her excursion with her mom who experienced Alzheimer's, sharing the illustrations she discovered that extended her heart and permitted her to embrace the worth of sympathy, compassion, and pride over her 14-year experience.

There is a wide scope of clinical phenomenology in Alzheimers disease, regarding the age of onset, presenting features, rate of progression and appearance of other clinical manifestation. Although clinical appearance and neuropathological hallmarks have been defining AD since its first description, major factors which trigger pathology are still unknown. The role of comorbidity is discussed controversially. Important environmental risk factors in AD development are continuous stress, low education and cardiovascular risk factors such as alcohol intake, smoking, hypertension. The role of lipids and cholesterol has been recognized, but the relevant pathogenetic steps are still to be identified. There is an urgent need to understand molecular disease pathogenesis in order to develop early therapeutic targets for the disease.

Research and Development is the vehicle by which organizations and economies create opportunity, innovation and secure a stream of future products and services.These outcomes are all critically important sources of sustainability in a world that is changing faster than most companies can keep up.The challenge behind them is the fundamental unpredictability of R&D; which is why effective project management is so important. Ron Basu's Managing Projects in Research and Development explains how and why project management can provide a means of helping to plan, organise and control multi-disciplinary research activities without stifling innovation. Combining research with practical examples and experience from a career that has included blue chip organizations such as GSK, GlaxoWellcome and Unilever, Ron Basu offers a rigorous guide to the fundamentals of R&D project management including project lifecycle management, risk management, cost, time quality and other success measures as well as the keys to operational excellence in this complicated world.

This book examines the relevance of current research for the early diagnosis of Alzheimer disease. It uncovers the present lack of clinical utility in research methodologies such as neuroimaging, drug challenges, electroencephalographs studies, and brain biopsy.